Study of Dosage Individualisation for the Treatment of Acute Myeloid Leukemia
Completed
- Conditions
- Acute Myeloid Leukemia
- Registration Number
- NCT00969891
- Lead Sponsor
- Mikkel Krogh-Madsen
- Brief Summary
The present study is not hypothesis driven but will explore the ability of pharmacokinetic-pharmacodynamic modelling to predict optimal dosage of the chemotherapeutic drugs used in therapy in adult patients with acute myeloid leukemia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 23
Inclusion Criteria
- adult men and women with newly diagnosed acute myeloid leukemia
Exclusion Criteria
- under age 18 years
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method significant covariates from the PK study after complete analysis of data
- Secondary Outcome Measures
Name Time Method Amount of the three drugs in patient plasma samples within 3 months of sampling
Trial Locations
- Locations (2)
Rigshospitalet, Hematology clinic
🇩🇰Copenhagen, Denmark
Herlev Hospital, Hematology Clinic
🇩🇰Herlev, Denmark
Rigshospitalet, Hematology clinic🇩🇰Copenhagen, Denmark